An Elevated Serum Lactate Dehydrogenase-to-albumin Ratio Is a Useful Poor Prognostic Predictor of Nivolumab in Patients With Gastric Cancer

Autor: Hiroomi Ogawa, Makoto Sohda, Kengo Kuriyama, Takayoshi Watanabe, Yasunari Ubukata, Ken Shirabe, Takehiko Yokobori, Hiroshi Saeki, Makoto Sakai, Arisa Yamaguchi, Hideyuki Saito, Nobuhiro Nakazawa, Akihiko Sano
Rok vydání: 2021
Předmět:
Zdroj: Anticancer Research. 41:3925-3931
ISSN: 1791-7530
0250-7005
Popis: Background/aim This study clarified the predictive impact of serum biomarkers on therapeutic sensitivity to nivolumab in patients with gastric cancer (GC). Patients and methods The outcomes of 27 patients who received nivolumab to treat postoperative recurrent or unresectable advanced GC were reviewed. Blood testing was performed immediately before and after two courses of nivolumab. We also focused on the rate of change of each blood variable. Results The decrease in albumin (Alb) levels (p=0.035) and increase in lactate dehydrogenase (LDH) levels (p=0.012) after two courses of nivolumab were significantly larger in patients with disease progression. Furthermore, therapeutic resistance was significantly associated with an elevated LDH-to-Alb ratio (LAR) after two courses of nivolumab. Conclusion Decreased Alb or increased LDH levels after two courses of nivolumab predicted nivolumab sensitivity in patients with GC. An increased LAR was a meaningful predictor of nivolumab resistance.
Databáze: OpenAIRE